Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thai Officials Say Compulsory Licenses Will Not Deter Biotech Business – BIO 2008 Exclusive

This article was originally published in PharmAsia News

Executive Summary

SAN DIEGO - Industry furor over Thailand's compulsory license position will not deter multinational companies from investing in the country, according to Thai officials who sat down with PharmAsia News during the BIO 2008 convention in San Diego

You may also be interested in...



Thailand Probes Compulsory License Clopidogrel Purchasing Woes

Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.

Thailand Probes Compulsory License Clopidogrel Purchasing Woes

Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.

Thailand Furthers Cost-Cutting Measures, Putting Additional Pressure On MNCs

The Thai government plans to institute more cost-cutting measures on drugs and services in the country – a plan that will put a tighter squeeze on MNCs operating in Thailand.

Related Content

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel